About HLB Catheter Technology
CathPrint A New Catheter Paradigm CathPrint AB has invented a production technology of catheters. an edge technology can be easily incorporated with other standard technologies to suit various different needs of catheter applications. It aims to allow extremely cost efficient production of catheters with high performance. CathPrintchar(2122) has the potential to revolutionize the production techniques of present catheters of all fields. The company's Technology The enabling for the establishment of CathPrint AB is a unique, patent-pending concept
Missing: HLB Catheter Technology's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: HLB Catheter Technology's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
HLB Catheter Technology Frequently Asked Questions (FAQ)
What is HLB Catheter Technology's latest funding round?
HLB Catheter Technology's latest funding round is Other Investors.
Who are the investors of HLB Catheter Technology?
Investors of HLB Catheter Technology include STING Capital.
Who are HLB Catheter Technology's competitors?
Competitors of HLB Catheter Technology include InterRad Medical, Paragon Medical, Onset Medical, Lutonix, LumenVu and 10 more.
Compare HLB Catheter Technology to Competitors
Stent systems develops angioplasty catheters and guidewires, and related interventional products
Varix Medical Corporation, located in Sunnyvale, Calif., is a medical device company focused on developing products for the minimally invasive treatment of chronic venous insufficiency, commonly referred to as "varicose veins." For patients with advanced stages of varicose veins, laser- and RF-based (radiofrequency) treatments have been developed, but each device has deficiencies making them less-than-optimal solutions. Varix Medical's platform technology will enable physicians to efficiently and effectively treat more types of diseased veins than is currently possible when using either laser or RF devices. Additional treatable vessels include tortuous sub-truncal vessels and other visible smaller varicose veins. The Varix platform employs a vapor-based endovenous ablation system that will consist of a disposable catheter, a catheter introducer or delivery system, and a reusable vapor generator. RCT and Coronis Medical Ventures LLC., formed Varix in August 2007 and acquired the technology under license from Tsunami MedTech LLC. Coronis and RCT have been the primary in investors in Varix.
InterRad Medical is developing a catheter anchoring device called SecurAcath Catheter Retention System. The SecurAcath System is a new and method for holding catheters in place over and extended time. The SecurAcath System aims to utilize a very small anchor that deploys just under the skin to hold a catheter securely in place.
Rafael Medical has developed a novel anchoring system for safely implanting and retrieving a wide range of intra-vascular devices in a minimally invasive manner. Based on the technology, diagnostic and therapeutic devices can be delivered into small and large blood vessels alike by way of a small-sized delivery system. Following the completion of the SafeFlo Filter the company is now developing additional devices geared to the interventional cardiology market.
Optim designs, develops, manufactures, and markets imaging products and accessories that help professionals in the medical, law enforcement, and industrial markets perform visualization procedures more effectively and efficiently. The ENTity Series for medical and the FreedomView Series for industrial and security markets utilize the company's OptiLux LED lighting technology freeing users from tethered or bulky external devices. Optim owns the trademarks for Optim, ENTity, FreedomView, and OptiLux.
Fox Hollow Technologies, Inc. has developed a coronary catheter that facilitates complete coronary lesion de-bulking, which has been shown to significantly reduce restenosis. The company's technology is designed to address the needs of the interventional cardiologist for a process that has traditionally been complex and has not allowed for complete de-bulking.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.